May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?

Abstract

Purpose

Hepatocellular carcinoma (HCC) ranks fifth among the common cancers worldwide. Hepatocarcinogenesis is a multiple-phases process, which involves changes in cellular genomes including high cell proliferation.In this study, we aimed to evaluate the relationship of NGAL level at the time of diagnosis with mortality in patients diagnosed with HCC.

Material and Methods

A total of 35 patients who developed HCC on the ground of HBV(+) and 30 healthy subjects were included in the study. Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria were used for staging of the patients with HCC.

Results

The mean age of all patients was 59.54 ± 11.57 years. Seventeen (48.6%) HCC patients died during 1-year follow-up. Survival of the patients who met the Milan criteria was longer (log-rank (Mantel-Cox) test, χ2 = 5.353, p = 0.021). Kaplan-Meier curve was drawn for NGAL cut-off value, mortality was found to be higher in patients with a NGAL level higher than 217.50 (log-rank (Mantel-Cox) test, χ2 = 15.540, p < 0.001).

Conclusion

In this study, we found that high levels of NGAL at the time of diagnosis were associated with poor prognosis in HCC patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.

    PubMed  Google Scholar 

  2. 2.

    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Forner A, Llovet JM, Bruix J. Hepatocellularcarcinoma. Lancet. 2012;379(9822):1245.

    Google Scholar 

  4. 4.

    Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2005;25(2):236–41.

    PubMed  Google Scholar 

  5. 5.

    Mehmet A, Dertli R. Serum soluble TWEAK concentration is decreased in patients with hepatocellular cancer and low blood levels of sTWEAK are associated with poor survival. Int J Hematol Oncol. 27(2):118–26.

  6. 6.

    Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65.

    CAS  PubMed  Google Scholar 

  7. 7.

    Rodvold JJ, Mahadevan NR, Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 2012;316(2):132–8.

    CAS  PubMed  Google Scholar 

  8. 8.

    Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine. 2011;56(2):435–41.

    CAS  PubMed  Google Scholar 

  9. 9.

    Jin D, Zhang Y, Chen X. Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells. Mol Cell Biochem. 2011;351(1-2):165–72.

    CAS  PubMed  Google Scholar 

  10. 10.

    Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2011;226(2):309–14.

    CAS  PubMed  Google Scholar 

  11. 11.

    Lin H-H, Liao C-J, Lee Y-C, Hu K-H, Meng H-W, Chu S-T. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci. 2011;7(1):74–86.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120(11):2426–34.

    CAS  PubMed  Google Scholar 

  13. 13.

    Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 1998;122(1):209–14.

    CAS  PubMed  Google Scholar 

  14. 14.

    Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43(12):1869–76.

    CAS  PubMed  Google Scholar 

  15. 15.

    Barresi V, Vitarelli E, Bonetti LR, Tuccari G, Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. Virchows Archiv. 2012;460(3):319–25.

    CAS  PubMed  Google Scholar 

  16. 16.

    Ozemir IA, Aslan S, Eren T, Bayraktar B, Bilgic C, Isbilen B, et al. The diagnostic and prognostic significance of serum neutrophil gelatinase-associated lipocalin levels in patients with colorectal cancer. Chirurgia (Bucharest, Romania: 1990). 2016;111(5):414–21.

    Google Scholar 

  17. 17.

    Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033–43.

    CAS  PubMed  Google Scholar 

  18. 18.

    Patil MA, Chua M-S, Kuang-Hung P, Lin R, Lih C-J, Cheung S-T, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005;24(23):3737.

    CAS  PubMed  Google Scholar 

  19. 19.

    Lee E-K, Kim H-J, Lee K-J, Lee H-J, Lee J-S, Kim D-G, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011;38(2):325–33.

    CAS  PubMed  Google Scholar 

  20. 20.

    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–28.

    CAS  PubMed  Google Scholar 

  21. 21.

    Llovet JM, Brú C, Bruix J, editors. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease; 1999: © 1999 by Thieme Medical Publishers, Inc.

  22. 22.

    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.

    CAS  PubMed  Google Scholar 

  23. 23.

    Stejskal D, Karpíšek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008;40(06):381–5.

    CAS  PubMed  Google Scholar 

  24. 24.

    Giasson J, Hua Li G, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2011;10(4):272–82.

    CAS  Google Scholar 

  25. 25.

    Mir SU, Jin L, Craven RJ. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem. 2012;287(18):14494–501.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8(15):2347–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Bouchet S, Bauvois B. Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers. 2014;6(2):796–812.

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36(5):e294–e9.

    CAS  PubMed  Google Scholar 

  29. 29.

    Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37(1):198–207.

    CAS  PubMed  Google Scholar 

  30. 30.

    Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology. 2013;58(4):1349–61.

    CAS  PubMed  Google Scholar 

  31. 31.

    Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β: a proteomic analysis. Biotechnol Bioeng. 2005;91(4):502–15.

    CAS  PubMed  Google Scholar 

  32. 32.

    Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J Immunol. 2003;171(12):6630–9.

    CAS  PubMed  Google Scholar 

  33. 33.

    Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2(2):90–7 quiz 1 p following 113.

    CAS  PubMed  Google Scholar 

  34. 34.

    Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis. 2010;27(5):295–305.

    CAS  PubMed  Google Scholar 

  35. 35.

    Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer M-L, Mantion G, Delhorme J-B, et al. A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer. 2014;14(1):912.

    PubMed  PubMed Central  Google Scholar 

  36. 36.

    Friedl A, Stoesz S, Buckley P, Gould M. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31(7):433–41.

    CAS  PubMed  Google Scholar 

  37. 37.

    Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012;2.

  38. 38.

    Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98(9):1540–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Tong Z, Wu X, Ovcharenko D, Zhu J, Chen C-S, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005;391(2):441–8.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ramazan Dertli.

Ethics declarations

This study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The ethical approval was received from the ethical committee of Necmettin Erbakan University Meram Medical Faculty.

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dertli, R., Biyik, M., Yolacan, R. et al. May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?. J Gastrointest Canc 51, 932–938 (2020). https://doi.org/10.1007/s12029-019-00323-9

Download citation

Keywords

  • ords: Hepatocellular carcinoma
  • lipocalin-2
  • Neutrophil gelatinase-associated lipocalin